The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / PAD2 & PAD4 Modulate Immune Response in TLR-7-Dependent Lupus

PAD2 & PAD4 Modulate Immune Response in TLR-7-Dependent Lupus

January 28, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients and mice with systemic lupus erythematosus (SLE) experience endothelial dysfunction and vascular damage, both of which may result from increased induction of neutrophil extracellular traps (NETs). NETs can amplify pathogenic type I interferon (IFN) responses. Studies in genetically prone murine models of lupus have found inhibitors of the peptidyl arginine deiminases (PAD) that block PAD2 and PAD4 are immunoprotective for lupus, renal disease and endothelial dysfunction.

You Might Also Like
  • Innate Immune Response Enters Center Stage for Inflammatory Eye Disease
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • IL-26 Plays Antimicrobial Role in Immune Response
Also By This Author
  • Treating Lupus: Strategies, Treat to Target & Biologics

Recent research suggests compounds that target PADs may be useful therapies for lupus and T cell-mediated disease. The study, from Yudong Liu of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Md., and colleagues, describes the role specific PAD enzymes play in the development of toll-like receptor (TLR) 7-dependent lupus autoimmunity and associated organ and vascular damage. Their results were published online in JCI Insight.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We have identified differential regulation and modulation of autoimmune responses, gene expression in secondary lymphoid organs and endothelial dysfunction by the isozyme PAD2 and PAD4 in TLR7-dependent autoimmunity and potentially pathogenic T cell responses,” write the authors in their discussion. “Given that both isozymes appear to play differential roles in the modulation of immune responses, the use of chemical inhibitors that target both PAD2 and PAD4 should be further examined for the potential to provide complimentary therapeutic effects in the treatment of autoimmune conditions characterized by aberrant innate and adaptive immune response, such as SLE.”

Methods
The investigators began the research using the inducible mouse model of TLR-7-dependent lupus-like disease (FVB), as well as Padi2-/- and Padi4-/- mice on the same background. They induced lupus in these mice by administering the TLR-7-agonist imiquimod. They then examined neutrophils from the FVB mice and PAD2 and PAD4 knockout mice to see the effect of imiquimod on NET induction. Researchers found that although neutrophils from PAD4 knockout mice produced fewer NETs than those from wild type or PAD2 knockout mice, all mice produced NETs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When the researchers compared detailed RNA sequencing (RNA-Seq) from lymph nodes and spleens in mice lacking PAD2 and PAD4, they found distinct transcriptional modulation in response to in vivo TLR-7 stimulation. Although the PAD2 knockout mice showed decrease T helper subset polarization than the other mice, the PAD4 knockout mice displayed decreased autoantibodies, type I IFN responses, immune cell activation and vascular dysfunction. The investigators then turned their attention to human T cells that express both PADs and found treatment with PAD 2 and/or PAD4 inhibitors inhibited Th1 polarization.

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: endothelial dysfunction, neutrophil extracellular traps, systemic lupus erythematosus (SLE), TLR-7

You Might Also Like:
  • Innate Immune Response Enters Center Stage for Inflammatory Eye Disease
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • IL-26 Plays Antimicrobial Role in Immune Response
  • 2015 ACR/ARHP Annual Meeting: Immune Mediators Can Impact Inflammatory Response

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)